Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

WHAT ARE FOCUS AREAS IN CUTANEOUS LYMPHOMA RESEARCH?

New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma

For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL. 

Epigenetics & Biology of Cutaneous T-cell Lymphomas

These are exciting times in cutaneous T-cell lymphoma (CTCL) research. The hard work of laboratory and clinical investigators worldwide is starting to bear fruit, and a number of basic discoveries in the genetic and epigenetic foundations of CTCL are now being translated into novel therapies, with great impact for patients.

Medical Meeting Highlights: 3rd World Congress, T-Cell Lymphoma Forum and USCLC Annual Workshop

In a world that has 7,000 known rare diseases, with only 5% having any treatment available, the future of discovery and new treatment development in cutaneous lymphoma is promising. There is much hope for a brighter future for everyone living with this condition.

Industry Spotlight: Soligenix

Soligenix, Inc. recently to talk about their clinical trial for treating early stage cutaneous lymphoma. The treatment process uses a new topical photosensitizing agent (synthetic hypericin) and fluorescent light.

Industry Spotlight: Elorac

Elorac, Inc. is currently engaged in a Phase III clinical trial for topical naloxone, which targets itch in cutaneous lymphoma. Listen to the discussion to learn more about this innovative approach to managing the intense itch associated with the disease. 

Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Cutaneous T-cell lymphomas (CTCLs) primarily affect skin and are characterized by proliferation of mature CD4+ T-helper cells. The pattern of cytokine production in the skin and blood is considered to be of major importance for the pathogenesis of CTCLs.
Key Points:
IL-13 is an autocrine factor for CTCL.
IL-13 and its receptors represent novel markers of CTCL malignancy and potential therapeutic targets for intervention.

Novel Tumor Markers for CTCL Identified

IL-13 has been identified as an autocrine factor for cutaneous T-cell lymphomas (CTCL) and its receptors may be novel tumor markers for the disease, serving as potential therapeutic targets, results of a study published recently in Blood showed.

Low-dose total skin electron beam therapy

Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials.

CLARIONS Recipient Presents Research Abstract

2014 CLARIONS Research Award recipient Tae Jin Kim, PhD has had his abstract titled Flexible Dosimeter Bands for Whole-Body Dosimetry  accepted for an oral presentation at AAPM (The American Association of Physicists in Medicine) 58th Annual Meeting & Exhibition. The focus of Dr. Kim's research is developing a flexible radiation detector (dosimeter), which he has tested on a preclinical X-ray system, and is currently designing a readout device. Dr. Kim is a Postdoctoral Fellow in the Department of Radiation Oncology (Medical Physics) at Stanford University School of Medicine.

The Cutaneous Lymphoma Foundation is pleased to support this ground-breaking research through our CLARIONS Research Award Program.

FUTURE DIRECTIONS IN T-CELL CUTANEOUS LYMPHOMA

Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.